{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:43:09Z","timestamp":1790800989382,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"crossref","award":["1-R01-MH-111389"],"award-info":[{"award-number":["1-R01-MH-111389"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007928","name":"Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>Reducing the risk of HIV-associated neurocognitive disorders (HAND) is an elusive treatment goal for people living with HIV. Combination antiretroviral therapy (cART) has reduced the prevalence of HIV-associated dementia, but milder, disabling HAND is an unmet challenge. As newer cART regimens that more consistently suppress central nervous system (CNS) HIV replication are developed, the testing of adjunctive neuroprotective therapies must accelerate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>Successes in modifying cART regimens for CNS efficacy (penetrance, chemokine receptor targeting) and delivery (nanoformulations) in pilot studies suggest that improving cART neuroprotection and reducing HAND risk is achievable. Additionally, drugs currently used in neuroinflammatory, neuropsychiatric, and metabolic disorders show promise as adjuncts to cART, likely by broadly targeting neuroinflammation, oxidative stress, aerobic metabolism, and\/or neurotransmitter metabolism. Adjunctive cognitive brain therapy and aerobic exercise may provide additional efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Adjunctive neuroprotective therapies, including available FDA-approved drugs, cognitive therapy, and aerobic exercise combined with improved cART offer plausible strategies for optimizing the prevention and treatment of HAND.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11904-022-00612-2","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T10:03:13Z","timestamp":1658484193000},"page":"344-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND)"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-5726","authenticated-orcid":false,"given":"Dennis L.","family":"Kolson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"612_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","volume":"69","author":"A Antinori","year":"2007","unstructured":"Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789\u201399.","journal-title":"Neurology"},{"key":"612_CR2","doi-asserted-by":"publisher","first-page":"e2610","DOI":"10.1212\/WNL.0000000000010752","volume":"95","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu M, Lu Q, et al. Global prevalence and burden of HIV-associated neurocognitive disorder: a meta-analysis. Neurology. 2020;95:e2610\u201321.","journal-title":"Neurology"},{"key":"612_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/cid\/ciu862","volume":"60","author":"RK Heaton","year":"2015","unstructured":"Heaton RK, Franklin DR Jr, Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015;60:473\u201380.","journal-title":"Clin Infect Dis"},{"key":"612_CR4","doi-asserted-by":"publisher","unstructured":"\u2022 Chan P, Kerr SJ, Kroon E, et al. Cognitive trajectories after treatment in acute HIV infection. AIDS. 2021;35(6):883\u20138. https:\/\/doi.org\/10.1097\/QAD.0000000000002831. Immediate suppressive ART in AHI improves and sustains cognitive function in multiple domains for up to 6 years, with the largest improvements in patients with the poorest baseline cognitive functioning. Provides support for earliest possible intervention with cART, and suggests possible window of opportunity for early adjunctive therapies.","DOI":"10.1097\/QAD.0000000000002831"},{"key":"612_CR5","doi-asserted-by":"crossref","unstructured":"\u2022 Bougea A, Spantideas N, Galanis P, et al. Optimal treatment of HIV-associated neurocognitive disorders: myths and reality. A critical review. Ther Adv Infect Dis. 2019;6:2049936119838228. This is an up-to-date, comprehensive review that adds important perspective to treatment of HIV-NCI.","DOI":"10.1177\/2049936119838228"},{"key":"612_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","volume":"75","author":"RK Heaton","year":"2010","unstructured":"Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087\u201396.","journal-title":"Neurology"},{"key":"612_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1474-4422(14)70137-1","volume":"13","author":"S Nightingale","year":"2014","unstructured":"Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13:1139\u201351.","journal-title":"Lancet Neurol"},{"key":"612_CR8","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Lin SP, Calcagno A, Letendre SL, et al. Clinical treatment options and randomized clinical trials for neurocognitive complications of HIV infection: combination antiretroviral therapy, central nervous system penetration effectiveness, and adjuvants. Curr Top Behav Neurosci. 2021;50:517\u2013545. A very comprehensive review of cross-sectional, prospective, and randomized controlled trials of CPE-rated regimens in HIV-NCI.","DOI":"10.1007\/7854_2020_186"},{"key":"612_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrn2040","volume":"8","author":"R Ellis","year":"2007","unstructured":"Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8:33\u201344.","journal-title":"Nat Rev Neurosci"},{"key":"612_CR10","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3851\/IMP2411","volume":"17","author":"CM Shikuma","year":"2012","unstructured":"Shikuma CM, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012;17:1233\u201342.","journal-title":"Antivir Ther"},{"key":"612_CR11","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/infdis\/jis104","volume":"205","author":"JT Grennan","year":"2012","unstructured":"Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205:1230\u20138.","journal-title":"J Infect Dis"},{"key":"612_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/COH.0000000000000105","volume":"9","author":"MF Chen","year":"2014","unstructured":"Chen MF, Gill AJ, Kolson DL. Neuropathogenesis of HIV-associated neurocognitive disorders: roles for immune activation, HIV blipping and viral tropism. Curr Opin HIV AIDS. 2014;9:559\u201364.","journal-title":"Curr Opin HIV AIDS"},{"key":"612_CR13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1086\/657342","volume":"202","author":"A Eden","year":"2010","unstructured":"Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202:1819\u201325.","journal-title":"J Infect Dis"},{"key":"612_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archneurol.2007.31","volume":"65","author":"S Letendre","year":"2008","unstructured":"Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65\u201370.","journal-title":"Arch Neurol"},{"key":"612_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/QAI.0b013e318274e2b0","volume":"62","author":"A Cusini","year":"2013","unstructured":"Cusini A, Vernazza PL, Yerly S, et al. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr. 2013;62:28\u201335.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1093\/infdis\/jir667","volume":"204","author":"V Dahl","year":"2011","unstructured":"Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011;204:1936\u201345.","journal-title":"J Infect Dis"},{"key":"612_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3851\/IMP1917","volume":"17","author":"JM Llibre","year":"2012","unstructured":"Llibre JM, Buzon MJ, Massanella M, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther. 2012;17:355\u201364.","journal-title":"Antivir Ther"},{"key":"612_CR18","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Force G, Ghout I, Ropers J, et al. Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study. J Antimicrob Chemother. 2021;76:743\u2013752. A relatively small (n=49 patients), but well-designed prospective ART intensification study of several different CPE-based ART regimens.","DOI":"10.1093\/jac\/dkaa473"},{"key":"612_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4049\/jimmunol.0900274","volume":"183","author":"H Dou","year":"2009","unstructured":"Dou H, Grotepas CB, McMillan JM, et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol. 2009;183:661\u20139.","journal-title":"J Immunol"},{"key":"612_CR20","first-page":"1757","volume":"9","author":"MJ Gomes","year":"2014","unstructured":"Gomes MJ, Neves J, Sarmento B. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomed. 2014;9:1757\u201369.","journal-title":"Int J Nanomed"},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2217\/nnm.09.38","volume":"4","author":"A Nowacek","year":"2009","unstructured":"Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond). 2009;4:557\u201374.","journal-title":"Nanomedicine (Lond)"},{"key":"612_CR22","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17425247.2017.1288212","volume":"14","author":"B Edagwa","year":"2017","unstructured":"Edagwa B, McMillan J, Sillman B, et al. Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv. 2017;14:1281\u201391.","journal-title":"Expert Opin Drug Deliv"},{"key":"612_CR23","doi-asserted-by":"publisher","unstructured":"McMillan J, Szlachetka A, Slack L, et al. Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques. Antimicrob Agents Chemother. 2017;62(1):e01316\u201317. https:\/\/doi.org\/10.1128\/AAC.01316-17.","DOI":"10.1128\/AAC.01316-17"},{"key":"612_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13365-014-0279-x","volume":"20","author":"LC Ndhlovu","year":"2014","unstructured":"Ndhlovu LC, Umaki T, Chew GM, et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neurovirol. 2014;20:571\u201382.","journal-title":"J Neurovirol"},{"key":"612_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/QAD.0000000000000951","volume":"30","author":"TM Gates","year":"2016","unstructured":"Gates TM, Cysique LA, Siefried KJ, et al. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS. 2016;30:591\u2013600.","journal-title":"AIDS"},{"key":"612_CR26","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Martin-Blondel G, Brassat D, Bauer J, et al. CCR5 blockade for neuroinflammatory diseases--beyond control of HIV. Nat Rev Neurol. 2016;12:95\u2013105. This thought-provoking review presents a thorough insight into the multiple potential mechanisms through which CCR5 blockade could provide neuroprotection in both infectious and non-infectious neuroinflammatory diseases.","DOI":"10.1038\/nrneurol.2015.248"},{"key":"612_CR27","doi-asserted-by":"publisher","unstructured":"Leon-Rivera R, Veenstra M, Donoso M, et al. Central nervous system (CNS) viral seeding by mature monocytes and potential therapies to reduce CNS viral reservoirs in the cART era. mBio. 2021;12(2):e03633\u201320. https:\/\/doi.org\/10.1128\/mBio.03633-20.","DOI":"10.1128\/mBio.03633-20"},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1570162X12666140526114526","volume":"12","author":"DW Williams","year":"2014","unstructured":"Williams DW, Veenstra M, Gaskill PJ, et al. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res. 2014;12:85\u201396.","journal-title":"Curr HIV Res"},{"key":"612_CR29","doi-asserted-by":"crossref","unstructured":"\u2022 D'Antoni ML, Paul RH, Mitchell BI, et al. Improved cognitive performance and reduced monocyte activation in virally suppressed chronic HIV after dual CCR2 and CCR5 antagonism. J Acquir Immune Defic Syndr. 2018;79:108\u2013116. An open-label 24-week study demonstrating improved NP test performance and reduced monocyte activation in virally suppressed patients treated with cenicriviroc.","DOI":"10.1097\/QAI.0000000000001752"},{"key":"612_CR30","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Christensen BL, Tan DH. An up-to-date evaluation of dolutegravir\/abacavir\/lamivudine for the treatment of HIV. Expert Opin Pharmacother. 2022;23:439\u2013446. A truly comprehensive up-to-date summary of DTG\/ABC\/3TC efficacy and where this regimen stands as a first-line treatment for HIV.","DOI":"10.1080\/14656566.2022.2029409"},{"key":"612_CR31","doi-asserted-by":"publisher","unstructured":"\u2022 Diggins CE, Russo SC, Lo J. Metabolic consequences of antiretroviral therapy. Curr HIV\/AIDS Rep. 2022;19(2):141\u201353. https:\/\/doi.org\/10.1007\/s11904-022-00600-6. A very useful review of adverse metabolic effects of current ART regimens","DOI":"10.1007\/s11904-022-00600-6"},{"key":"612_CR32","doi-asserted-by":"crossref","unstructured":"\u2022 O'Halloran JA, Cooley SA, Strain JF, et al. Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors. AIDS. 2019;33:1477\u20131483. A large (n=202 patients), provocative cross-sectional neuroimaging study suggesting reduced brain integrity in INSTI users.","DOI":"10.1097\/QAD.0000000000002236"},{"key":"612_CR33","doi-asserted-by":"crossref","unstructured":"\u2022 Prats A, Martinez-Zalacain I, Mothe B, et al. Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection. Sci Rep. 2021;11:11289. A prospective, controlled study of men LWH with matched seronegative controls. INSTI initiation before 3 months or later than 6 months after HIV infection associated with no cognitive differences, but with less loss of brain integrity.","DOI":"10.1038\/s41598-021-90678-6"},{"key":"612_CR34","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Chan P, Goh O, Kroon E, et al. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort. AIDS Res Ther. 2020;17:1. A large (n = 254) AHI patients in the RV254 Thai cohort that suggests depressive symptoms associate with DTG use.","DOI":"10.1186\/s12981-019-0257-8"},{"issue":"2","key":"612_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11904-022-00600-6","volume":"19","author":"T Lanman","year":"2019","unstructured":"Lanman T, Letendre S, Ma Q, et al. CNS neurotoxicity of antiretrovirals. J Neuroimmune Pharmacol. 2019;16(1):130\u201343. https:\/\/doi.org\/10.1007\/s11481-019-09886-7.","journal-title":"J Neuroimmune Pharmacol"},{"key":"612_CR36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s13365-012-0120-3","volume":"18","author":"K Robertson","year":"2012","unstructured":"Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012;18:388\u201399.","journal-title":"J Neurovirol"},{"key":"612_CR37","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/QAD.0b013e32832c4152","volume":"23","author":"CM Marra","year":"2009","unstructured":"Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359\u201366.","journal-title":"AIDS"},{"key":"612_CR38","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Pereira GFM, Kim A, Jalil EM, et al. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 2021;8:e33-e41. An important, large retrospective outcomes study of DTG use in pregnancy, demonstrating no DTG risk for neural tube defects.","DOI":"10.1016\/S2352-3018(20)30268-X"},{"key":"612_CR39","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Abrams E, Myer L. Lessons from dolutegravir and neural tube defects. Lancet HIV. 2021;8:e3-e4. A commentary that convincingly argues in favor of the benefits of DTG use during pregnancy.","DOI":"10.1016\/S2352-3018(20)30280-0"},{"key":"612_CR40","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s11481-013-9444-x","volume":"8","author":"L Uzasci","year":"2013","unstructured":"Uzasci L, Nath A, Cotter R. Oxidative stress and the HIV-infected brain proteome. J Neuroimmune Pharmacol. 2013;8:1167\u201380.","journal-title":"J Neuroimmune Pharmacol"},{"key":"612_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/WCO.0000000000000807","volume":"33","author":"JC McArthur","year":"2020","unstructured":"McArthur JC, Johnson TP. Chronic inflammation mediates brain injury in HIV infection: relevance for cure strategies. Curr Opin Neurol. 2020;33:397\u2013404.","journal-title":"Curr Opin Neurol"},{"key":"612_CR42","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/nm1511","volume":"12","author":"JM Brenchley","year":"2006","unstructured":"Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365\u201371.","journal-title":"Nat Med"},{"key":"612_CR43","doi-asserted-by":"publisher","first-page":"e2516","DOI":"10.1371\/journal.pone.0002516","volume":"3","author":"P Ancuta","year":"2008","unstructured":"Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE. 2008;3:e2516.","journal-title":"PLoS ONE"},{"key":"612_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-0034-1372337","volume":"34","author":"RW Price","year":"2014","unstructured":"Price RW, Spudich SS, Peterson J, et al. Evolving character of chronic central nervous system HIV infection. Semin Neurol. 2014;34:7\u201313.","journal-title":"Semin Neurol"},{"key":"612_CR45","first-page":"152","volume":"15","author":"AJ Stam","year":"2013","unstructured":"Stam AJ, Nijhuis M, van den Bergh WM, et al. Differential genotypic evolution of HIV-1 quasispecies in cerebrospinal fluid and plasma: a systematic review. AIDS Rev. 2013;15:152\u201361.","journal-title":"AIDS Rev"},{"key":"612_CR46","doi-asserted-by":"publisher","first-page":"5698931","DOI":"10.1155\/2016\/5698931","volume":"2016","author":"SK Biswas","year":"2016","unstructured":"Biswas SK. Does the Interdependence between oxidative stress and inflammation explain the antioxidant paradox? Oxid Med Cell Longev. 2016;2016:5698931.","journal-title":"Oxid Med Cell Longev"},{"key":"612_CR47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0166-2236(00)01819-1","volume":"24","author":"V Mollace","year":"2001","unstructured":"Mollace V, Nottet HS, Clayette P, et al. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci. 2001;24:411\u20136.","journal-title":"Trends Neurosci"},{"key":"612_CR48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.mito.2004.05.009","volume":"4","author":"V Valcour","year":"2004","unstructured":"Valcour V, Shiramizu B. HIV-associated dementia, mitochondrial dysfunction, and oxidative stress. Mitochondrion. 2004;4:119\u201329.","journal-title":"Mitochondrion"},{"key":"612_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0009-8981(94)90124-4","volume":"224","author":"DJ Malvy","year":"1994","unstructured":"Malvy DJ, Richard MJ, Arnaud J, et al. Relationship of plasma malondialdehyde, vitamin E and antioxidant micronutrients to human immunodeficiency virus-1 seropositivity. Clin Chim Acta. 1994;224:89\u201394.","journal-title":"Clin Chim Acta"},{"key":"612_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1423-0127-16-61","volume":"16","author":"DR Suresh","year":"2009","unstructured":"Suresh DR, Annam V, Pratibha K, et al. Total antioxidant capacity\u2013a novel early bio-chemical marker of oxidative stress in HIV infected individuals. J Biomed Sci. 2009;16:61.","journal-title":"J Biomed Sci"},{"key":"612_CR51","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1089\/aid.2009.0062","volume":"25","author":"A Wanchu","year":"2009","unstructured":"Wanchu A, Rana SV, Pallikkuth S, et al. Short communication: oxidative stress in HIV-infected individuals: a cross-sectional study. AIDS Res Hum Retroviruses. 2009;25:1307\u201311.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"612_CR52","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.4049\/jimmunol.149.10.3386","volume":"149","author":"N Israel","year":"1992","unstructured":"Israel N, Gougerot-Pocidalo MA, Aillet F, et al. Redox status of cells influences constitutive or induced NF-kappa B translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J Immunol. 1992;149:3386\u201393.","journal-title":"J Immunol"},{"key":"612_CR53","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1089\/aid.1996.12.1537","volume":"12","author":"AT Palamara","year":"1996","unstructured":"Palamara AT, Perno CF, Aquaro S, et al. Glutathione inhibits HIV replication by acting at late stages of the virus life cycle. AIDS Res Hum Retroviruses. 1996;12:1537\u201341.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"612_CR54","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF03401740","volume":"4","author":"J Fuchs","year":"1998","unstructured":"Fuchs J, Oelke N, Imhof M, et al. Multiparameter analysis of clastogenic factors, pro-oxidant cytokines, and inflammatory markers in HIV-1-infected patients with asymptomatic disease, opportunistic infections, and malignancies. Mol Med. 1998;4:333\u201343.","journal-title":"Mol Med"},{"key":"612_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0378-4274(99)00282-9","volume":"112\u2013113","author":"KE Driscoll","year":"2000","unstructured":"Driscoll KE. TNFalpha and MIP-2: role in particle-induced inflammation and regulation by oxidative stress. Toxicol Lett. 2000;112\u2013113:177\u201383.","journal-title":"Toxicol Lett"},{"key":"612_CR56","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1089\/ars.2017.7099","volume":"28","author":"G Aguilera","year":"2018","unstructured":"Aguilera G, Colin-Gonzalez AL, Rangel-Lopez E, et al. Redox signaling, neuroinflammation, and neurodegeneration. Antioxid Redox Signal. 2018;28:1626\u201351.","journal-title":"Antioxid Redox Signal"},{"key":"612_CR57","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/archneur.64.9.noc60125","volume":"64","author":"AC Roc","year":"2007","unstructured":"Roc AC, Ances BM, Chawla S, et al. Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Arch Neurol. 2007;64:1249\u201357.","journal-title":"Arch Neurol"},{"key":"612_CR58","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1212\/01.wnl.0000260610.79853.47","volume":"68","author":"VV Bandaru","year":"2007","unstructured":"Bandaru VV, McArthur JC, Sacktor N, et al. Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology. 2007;68:1481\u20137.","journal-title":"Neurology"},{"key":"612_CR59","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1086\/523648","volume":"196","author":"A Eden","year":"2007","unstructured":"Eden A, Price RW, Spudich S, et al. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis. 2007;196:1779\u201383.","journal-title":"J Infect Dis"},{"key":"612_CR60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1128\/CMR.00050-12","volume":"26","author":"G Marchetti","year":"2013","unstructured":"Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev. 2013;26:2\u201318.","journal-title":"Clin Microbiol Rev"},{"key":"612_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.coi.2015.06.004","volume":"36","author":"A Burgener","year":"2015","unstructured":"Burgener A, McGowan I, Klatt NR. HIV and mucosal barrier interactions: consequences for transmission and pathogenesis. Curr Opin Immunol. 2015;36:22\u201330.","journal-title":"Curr Opin Immunol"},{"key":"612_CR62","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/COH.0000000000000234","volume":"11","author":"AS Zevin","year":"2016","unstructured":"Zevin AS, McKinnon L, Burgener A, et al. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS. 2016;11:182\u201390.","journal-title":"Curr Opin HIV AIDS"},{"key":"612_CR63","doi-asserted-by":"publisher","first-page":"688886","DOI":"10.3389\/fimmu.2021.688886","volume":"12","author":"G Mak","year":"2021","unstructured":"Mak G, Zaunders JJ, Bailey M, et al. Preservation of gastrointestinal mucosal barrier function and microbiome in patients with controlled HIV infection. Front Immunol. 2021;12:688886.","journal-title":"Front Immunol"},{"key":"612_CR64","doi-asserted-by":"crossref","unstructured":"\u2022 Jiang W, Luo Z, Stephenson S, et al. Cerebrospinal fluid and plasma lipopolysaccharide levels in human immunodeficiency virus type 1 infection and associations with inflammation, blood-brain barrier permeability, and neuronal injury. J Infect Dis. 2021;223:1612\u20131620. A study that assesses both plasma and CSF LPS in viremic PLWH, and demonstrates the link between plasma LPS, increased blood-brain barrier permeability, and neuroinflammation.","DOI":"10.1093\/infdis\/jiaa765"},{"key":"612_CR65","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.tim.2012.09.001","volume":"21","author":"NR Klatt","year":"2013","unstructured":"Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013;21:6\u201313.","journal-title":"Trends Microbiol"},{"key":"612_CR66","doi-asserted-by":"publisher","first-page":"e70164","DOI":"10.1371\/journal.pone.0070164","volume":"8","author":"VG Valcour","year":"2013","unstructured":"Valcour VG, Ananworanich J, Agsalda M, et al. HIV DNA reservoir increases risk for cognitive disorders in cART-naive patients. PLoS ONE. 2013;8:e70164.","journal-title":"PLoS ONE"},{"key":"612_CR67","doi-asserted-by":"publisher","first-page":"100168","DOI":"10.1016\/j.bbih.2020.100168","volume":"9","author":"S Rich","year":"2020","unstructured":"Rich S, Klann E, Bryant V, et al. A review of potential microbiome-gut-brain axis mediated neurocognitive conditions in persons living with HIV. Brain Behav Immun Health. 2020;9:100168.","journal-title":"Brain Behav Immun Health"},{"key":"612_CR68","doi-asserted-by":"publisher","unstructured":"Ceccarelli G, Brenchley JM, Cavallari EN, et al. Impact of high-dose multi-strain probiotic supplementation on neurocognitive performance and central nervous system immune activation of HIV-1 infected individuals. Nutrients. 2017;9(11):1269. https:\/\/doi.org\/10.3390\/nu9111269.","DOI":"10.3390\/nu9111269"},{"key":"612_CR69","doi-asserted-by":"publisher","first-page":"e00756","DOI":"10.1002\/brb3.756","volume":"7","author":"G Ceccarelli","year":"2017","unstructured":"Ceccarelli G, Fratino M, Selvaggi C, et al. A pilot study on the effects of probiotic supplementation on neuropsychological performance and microRNA-29a-c levels in antiretroviral-treated HIV-1-infected patients. Brain Behav. 2017;7:e00756.","journal-title":"Brain Behav"},{"key":"612_CR70","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Angelovich TA, Churchill MJ, Wright EJ, et al. New potential axes of HIV neuropathogenesis with relevance to biomarkers and treatment. In: Cysique, L.A., Rourke, S.B. (eds) Neurocognitive Complications of HIV-Infection. Current Topics in Behavioral Neurosciences, vol 50. Springer, Cham. https:\/\/doi.org\/10.1007\/7854_2019_126. A comprehensive update on HIV neuropathogenesis, relevant biomarkers, and treatment priorities.","DOI":"10.1007\/7854_2019_126"},{"key":"612_CR71","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1212\/NXI.0000000000000551","volume":"6","author":"B Ambrosius","year":"2019","unstructured":"Ambrosius B, Gold R, Chan A, et al. Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy. Neurol Neuroimmunol Neuroinflamm. 2019;6:e551.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"612_CR72","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2174\/157488912803252023","volume":"7","author":"G Joshi","year":"2012","unstructured":"Joshi G, Johnson JA. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov. 2012;7:218\u201329.","journal-title":"Recent Pat CNS Drug Discov"},{"key":"612_CR73","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/gene.2011.76","volume":"13","author":"L Seu","year":"2012","unstructured":"Seu L, Burt TD, Witte JS, et al. Variations in the heme oxygenase-1 microsatellite polymorphism are associated with plasma CD14 and viral load in HIV-infected African-Americans. Genes Immun. 2012;13:258\u201367.","journal-title":"Genes Immun"},{"key":"612_CR74","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12192-011-0309-z","volume":"17","author":"M Chen","year":"2012","unstructured":"Chen M, Zhou L, Ding H, et al. Short (GT) ( n ) repeats in heme oxygenase-1 gene promoter are associated with lower risk of coronary heart disease in subjects with high levels of oxidative stress. Cell Stress Chaperones. 2012;17:329\u201338.","journal-title":"Cell Stress Chaperones"},{"key":"612_CR75","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12974-018-1102-z","volume":"15","author":"AJ Gill","year":"2018","unstructured":"Gill AJ, Garza R, Ambegaokar SS, et al. Heme oxygenase-1 promoter region (GT)n polymorphism associates with increased neuroimmune activation and risk for encephalitis in HIV infection. J Neuroinflamm. 2018;15:70.","journal-title":"J Neuroinflamm"},{"key":"612_CR76","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11904-014-0210-3","volume":"11","author":"AJ Gill","year":"2014","unstructured":"Gill AJ, Kolson DL. Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence. Curr HIV\/AIDS Rep. 2014;11:325\u201335.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"612_CR77","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1172\/JCI72279","volume":"124","author":"AJ Gill","year":"2014","unstructured":"Gill AJ, Kovacsics CE, Cross SA, et al. Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders. J Clin Invest. 2014;124:4459\u201372.","journal-title":"J Clin Invest"},{"key":"612_CR78","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/glia.23160","volume":"65","author":"CE Kovacsics","year":"2017","unstructured":"Kovacsics CE, Gill AJ, Ambegaokar SS, et al. Degradation of heme oxygenase-1 by the immunoproteasome in astrocytes: a potential interferon-gamma-dependent mechanism contributing to HIV neuropathogenesis. Glia. 2017;65:1264\u201377.","journal-title":"Glia"},{"key":"612_CR79","doi-asserted-by":"publisher","unstructured":"\u2022 Garza R, Gill AJ, Bastien BL, et al. Heme oxygenase-1 promoter (GT) n polymorphism associates with HIV neurocognitive impairment. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e710. https:\/\/doi.org\/10.1212\/NXI.0000000000000710. Using the CHARTER cohort, investigators demonstrated a significant risk-reduction for HIV-NCI in African-Americans with short (GT)n dinucleotide repeats in the HMOX1 promoter.","DOI":"10.1212\/NXI.0000000000000710"},{"key":"612_CR80","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1615\/CritRevImmunol.2013007247","volume":"33","author":"AJ Gill","year":"2013","unstructured":"Gill AJ, Kolson DL. Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol. 2013;33:307\u201359.","journal-title":"Crit Rev Immunol"},{"key":"612_CR81","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40265-015-0528-1","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2016;76:243\u201354.","journal-title":"Drugs"},{"key":"612_CR82","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.4049\/jimmunol.1101868","volume":"187","author":"SA Cross","year":"2011","unstructured":"Cross SA, Cook DR, Chi AW, et al. Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection. J Immunol. 2011;187:5015\u201325.","journal-title":"J Immunol"},{"key":"612_CR83","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12974-017-0829-2","volume":"14","author":"B Ambrosius","year":"2017","unstructured":"Ambrosius B, Faissner S, Guse K, et al. Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity. J Neuroinflamm. 2017;14:51.","journal-title":"J Neuroinflamm"},{"key":"612_CR84","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Kornberg MD, Bhargava P, Kim PM, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;\u00a0360(6387):449\u2013453. https:\/\/doi.org\/10.1126\/science.aan4665. This study identifies a potential immune-modulating neuroprotective mechanism of action of dimethylfumarate in the brain (switching from aerobic to anaerobic glycolysis), through studies of treated multiple sclerosis patients and animal models.","DOI":"10.1126\/science.aan4665"},{"key":"612_CR85","doi-asserted-by":"publisher","unstructured":"\u2022 Garcia-Mesa Y, Xu HE, Vance P, et al. Dimethyl fumarate, an approved multiple sclerosis treatment, reduces brain oxidative stress in SIV-infected rhesus macaques: potential therapeutic repurposing for HIV neuroprotection. Antioxidants 2021;10(3):416. https:\/\/doi.org\/10.3390\/antiox10030416. A pilot study of the FDA-approved drug, dimethyl fumarate, in SIV-infected, immune-deficient macques that demonstrated reduced DNA and protein oxidation in multiple brain regions during chronic oral administration.","DOI":"10.3390\/antiox10030416"},{"key":"612_CR86","doi-asserted-by":"crossref","unstructured":"\u2022 Robledinos-Anton N, Fernandez-Gines R, Manda G, et al. Activators and inhibitors of NRF2: a review of their potential for clinical development. Oxid Med Cell Longev. 2019;2019:9372182. A very useful introductory review of the topic of Nrf2 activators as therapeutics.","DOI":"10.1155\/2019\/9372182"},{"key":"612_CR87","doi-asserted-by":"publisher","unstructured":"Mansouri A, Reiner Z, Ruscica M, et al. Antioxidant effects of statins by modulating Nrf2 and Nrf2\/HO-1 signaling in different diseases. J Clin Med. 2022;11(5):1313. https:\/\/doi.org\/10.3390\/jcm11051313.","DOI":"10.3390\/jcm11051313"},{"key":"612_CR88","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/infdis\/jiq115","volume":"203","author":"A Ganesan","year":"2011","unstructured":"Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203:756\u201364.","journal-title":"J Infect Dis"},{"key":"612_CR89","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1093\/cid\/cit748","volume":"58","author":"NT Funderburg","year":"2014","unstructured":"Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58:588\u201395.","journal-title":"Clin Infect Dis"},{"key":"612_CR90","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrneurol.2015.35","volume":"11","author":"MC Power","year":"2015","unstructured":"Power MC, Weuve J, Sharrett AR, et al. Statins, cognition, and dementia-systematic review and methodological commentary. Nat Rev Neurol. 2015;11:220\u20139.","journal-title":"Nat Rev Neurol"},{"key":"612_CR91","doi-asserted-by":"publisher","unstructured":"Williams TE, Holdsworth KP, Nicholas JM, et al. Assessing neurofilaments as biomarkers of neuroprotection in progressive multiple sclerosis: from the MS-STAT randomized controlled trial. Neurol Neuroimmunol Neuroinflamm. 2022;9(2):e1130. https:\/\/doi.org\/10.1212\/NXI.0000000000001130.","DOI":"10.1212\/NXI.0000000000001130"},{"key":"612_CR92","doi-asserted-by":"crossref","unstructured":"\u2022 Stefanou MI, Palaiodimou L, Katsanos AH, et al. The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2022;58:103395. Failure of statins to demonstrate neurprotective effects in multiple sclerosis by neuroimaging and clinical criteria is comprehensively covered.","DOI":"10.1016\/j.msard.2021.103395"},{"key":"612_CR93","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1097\/QAD.0b013e32813384e8","volume":"21","author":"G Schifitto","year":"2007","unstructured":"Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007;21:1877\u201386.","journal-title":"AIDS"},{"key":"612_CR94","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1310\/hct1101-59","volume":"11","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, Navia BA, Marra CM, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010;11:59\u201367.","journal-title":"HIV Clin Trials"},{"key":"612_CR95","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0161-813X(03)00102-5","volume":"25","author":"K Magyar","year":"2004","unstructured":"Magyar K, Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology. 2004;25:233\u201342.","journal-title":"Neurotoxicology"},{"key":"612_CR96","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1212\/WNL.0b013e3181c51a48","volume":"73","author":"G Schifitto","year":"2009","unstructured":"Schifitto G, Yiannoutsos CT, Ernst T, et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology. 2009;73:1975\u201381.","journal-title":"Neurology"},{"key":"612_CR97","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1212\/01.wnl.0000268487.78753.0f","volume":"69","author":"G Schifitto","year":"2007","unstructured":"Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology. 2007;69:1314\u201321.","journal-title":"Neurology"},{"key":"612_CR98","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1046\/j.0953-816x.2001.01572.x","volume":"13","author":"N Tong","year":"2001","unstructured":"Tong N, Sanchez JF, Maggirwar SB, et al. Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci. 2001;13:1913\u201322.","journal-title":"Eur J Neurosci"},{"key":"612_CR99","doi-asserted-by":"publisher","first-page":"9162","DOI":"10.1523\/JNEUROSCI.23-27-09162.2003","volume":"23","author":"H Dou","year":"2003","unstructured":"Dou H, Birusingh K, Faraci J, et al. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci. 2003;23:9162\u201370.","journal-title":"J Neurosci"},{"key":"612_CR100","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1006\/mcne.2002.1196","volume":"21","author":"IP Everall","year":"2002","unstructured":"Everall IP, Bell C, Mallory M, et al. Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci. 2002;21:493\u2013501.","journal-title":"Mol Cell Neurosci"},{"key":"612_CR101","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1097\/01.aids.0000244208.49123.1b","volume":"20","author":"SL Letendre","year":"2006","unstructured":"Letendre SL, Woods SP, Ellis RJ, et al. Lithium improves HIV-associated neurocognitive impairment. AIDS. 2006;20:1885\u20138.","journal-title":"AIDS"},{"key":"612_CR102","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/13550280902758973","volume":"15","author":"G Schifitto","year":"2009","unstructured":"Schifitto G, Zhong J, Gill D, et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol. 2009;15:176\u201386.","journal-title":"J Neurovirol"},{"key":"612_CR103","doi-asserted-by":"publisher","first-page":"e5401","DOI":"10.1097\/MD.0000000000005401","volume":"95","author":"EH Decloedt","year":"2016","unstructured":"Decloedt EH, Freeman C, Howells F, et al. Moderate to severe HIV-associated neurocognitive impairment: a randomized placebo-controlled trial of lithium. Medicine (Baltimore). 2016;95:e5401.","journal-title":"Medicine (Baltimore)"},{"key":"612_CR104","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2377-6-42","volume":"6","author":"LA Cysique","year":"2006","unstructured":"Cysique LA, Maruff P, Brew BJ. Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study. BMC Neurol. 2006;6:42.","journal-title":"BMC Neurol"},{"key":"612_CR105","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1212\/01.wnl.0000204294.28189.03","volume":"66","author":"G Schifitto","year":"2006","unstructured":"Schifitto G, Peterson DR, Zhong J, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology. 2006;66:919\u201321.","journal-title":"Neurology"},{"key":"612_CR106","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Medeiros GC, Smith FA, Trivedi MH, et al. Depressive disorders in HIV\/AIDS: a clinically focused narrative review. Harv Rev Psychiatry. 2020;28:146\u2013158. A comprehensive, yet digestible guide for clinicians evaluating and treating depressive disorders in PLWH.","DOI":"10.1097\/HRP.0000000000000252"},{"key":"612_CR107","first-page":"CD008525","volume":"1","author":"I Eshun-Wilson","year":"2018","unstructured":"Eshun-Wilson I, Siegfried N, Akena DH, et al. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst Rev. 2018;1:CD008525.","journal-title":"Cochrane Database Syst Rev"},{"key":"612_CR108","doi-asserted-by":"crossref","unstructured":"\u2022 Stewart JC, Polanka BM, So-Armah KA, et al. Associations of total, cognitive\/affective, and somatic depressive symptoms and antidepressant use with cardiovascular disease-relevant biomarkers in HIV: veterans aging cohort study. Psychosom Med. 2020;82:461\u2013470. An important and comprehensive review of more than 2300 veterans linking cardiovascular disease favorable and unfavorable risk modulation with antidepressant use. The VACS cohort is revealing many important disease associations.","DOI":"10.1097\/PSY.0000000000000808"},{"key":"612_CR109","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/09540260701877670","volume":"20","author":"BM Ances","year":"2008","unstructured":"Ances BM, Letendre SL, Alexander T, et al. Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. Int Rev Psychiatry. 2008;20:89\u201393.","journal-title":"Int Rev Psychiatry"},{"key":"612_CR110","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11481-006-9054-y","volume":"2","author":"SL Letendre","year":"2007","unstructured":"Letendre SL, Marquie-Beck J, Ellis RJ, et al. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol. 2007;2:120\u20137.","journal-title":"J Neuroimmune Pharmacol"},{"key":"612_CR111","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s13365-017-0587-z","volume":"24","author":"N Sacktor","year":"2018","unstructured":"Sacktor N, Skolasky RL, Moxley R, et al. Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial. J Neurovirol. 2018;24:16\u201327.","journal-title":"J Neurovirol"},{"key":"612_CR112","doi-asserted-by":"publisher","first-page":"658705","DOI":"10.3389\/fneur.2021.658705","volume":"12","author":"A Ojagbemi","year":"2021","unstructured":"Ojagbemi A. HIV associated neurocognitive disorders subsidence through citalopram addition in anti-retroviral therapy (HANDS-CARE): a concept note. Front Neurol. 2021;12:658705.","journal-title":"Front Neurol"},{"key":"612_CR113","doi-asserted-by":"crossref","unstructured":"\u2022 McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet. 2021;398:1184\u20131194. A comprehensive, informative review of S1PR modulators that discusses potential uses of this class of drugs in systemic and CNS inflammatory and immune-mediated diseases.","DOI":"10.1016\/S0140-6736(21)00244-0"},{"key":"612_CR114","doi-asserted-by":"crossref","unstructured":"\u2022 Pino M, Paganini S, Deleage C, et al. Fingolimod retains cytolytic T cells and limits T follicular helper cell infection in lymphoid sites of SIV persistence. PLoS Pathog. 2019;15:e1008081. A novel study of an FDA-approved inhibitor of immune cell trafficking for targeting lymphoid tissues, with implications for HIV reservoir reduction studies.","DOI":"10.1371\/journal.ppat.1008081"},{"issue":"6","key":"612_CR115","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ana.26346","volume":"91","author":"I Kister","year":"2022","unstructured":"Kister I, Patskovsky Y, Curtin R, et al. Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study. Ann Neurol. 2022;91(6):782\u201395. https:\/\/doi.org\/10.1002\/ana.26346.","journal-title":"Ann Neurol"},{"key":"612_CR116","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.4049\/jimmunol.1202490","volume":"190","author":"KG Haanstra","year":"2013","unstructured":"Haanstra KG, Hofman SO, Lopes Estevao DM, et al. Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol. 2013;190:1961\u201373.","journal-title":"J Immunol"},{"key":"612_CR117","doi-asserted-by":"publisher","unstructured":"De Kleijn KMA, Martens GJM. Molecular effects of FDA-approved multiple sclerosis drugs on glial cells and neurons of the central nervous system. Int J Mol Sci. 2020;21(12):4229. https:\/\/doi.org\/10.3390\/ijms21124229.","DOI":"10.3390\/ijms21124229"},{"key":"612_CR118","doi-asserted-by":"publisher","first-page":"e1004533","DOI":"10.1371\/journal.ppat.1004533","volume":"10","author":"JH Campbell","year":"2014","unstructured":"Campbell JH, Ratai EM, Autissier P, et al. Anti-alpha4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infection. PLoS Pathog. 2014;10:e1004533.","journal-title":"PLoS Pathog"},{"key":"612_CR119","doi-asserted-by":"crossref","unstructured":"\u2022 Gaddam M, Singh A, Jain N, et al. A comprehensive review of intranasal insulin and its effect on the cognitive function of diabetics. Cureus. 2021;13:e17219. Highly informative review of beneficial effects of intranasal insulin on cognitive performance in diabetic patients that supports a rationale for further testing in other disorders.","DOI":"10.7759\/cureus.17219"},{"key":"612_CR120","doi-asserted-by":"crossref","unstructured":"\u2022 Craft S, Raman R, Chow TW, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77:1099\u20131109. First multisite phase 2\/3study of intranasal insulin for cognitive deficits in MCI or Alzheimer\u2019s disease showed no benefit over a 12-month period. It did confirm effective delivery approach and patient compliance.","DOI":"10.1001\/jamaneurol.2020.1840"},{"key":"612_CR121","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/hiv.12490","volume":"18","author":"AK Monroe","year":"2017","unstructured":"Monroe AK, Zhang L, Jacobson LP, et al. The association between physical activity and cognition in men with and without HIV infection. HIV Med. 2017;18:555\u201363.","journal-title":"HIV Med"},{"key":"612_CR122","doi-asserted-by":"crossref","unstructured":"\u2022 Dufour CA, Marquine MJ, Fazeli PL, et al. A longitudinal analysis of the impact of physical activity on neurocognitive functioning among HIV-infected adults. AIDS Behav. 2018;22:1562\u20131572. An important study (n=235 PLWH, 56 HIV-negative controls) demonstrating the consistent physical activity (> 50% of study visits) associates with better preservation of neurocognitive functioning in both PLWH and HIV-negative controls.","DOI":"10.1007\/s10461-016-1643-z"},{"key":"612_CR123","doi-asserted-by":"crossref","unstructured":"\u2022 Vance DE, Fazeli PL, Cheatwood J, et al. Targeting HIV-related neurocognitive impairments with cognitive training strategies: insights from the cognitive aging literature. Curr Top Behav Neurosci. 2021;50:503\u2013515. An informative study for all clinicians and researchers interested in cognitive outcomes in PLWH.","DOI":"10.1007\/7854_2018_80"},{"key":"612_CR124","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/JNC.0000000000000030","volume":"30","author":"DE Vance","year":"2019","unstructured":"Vance DE, Fazeli PL, Cheatwood J, et al. Computerized cognitive training for the neurocognitive complications of HIV infection: a systematic review. J Assoc Nurses AIDS Care. 2019;30:51\u201372.","journal-title":"J Assoc Nurses AIDS Care"},{"key":"612_CR125","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/cid\/cix645","volume":"65","author":"KM Erlandson","year":"2017","unstructured":"Erlandson KM, Kitch D, Wester CW, et al. The impact of statin and angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker therapy on cognitive function in adults with human immunodeficiency virus infection. Clin Infect Dis. 2017;65:2042\u20139.","journal-title":"Clin Infect Dis"},{"key":"612_CR126","doi-asserted-by":"publisher","first-page":"117512","DOI":"10.1016\/j.neuroimage.2020.117512","volume":"225","author":"T Tarumi","year":"2021","unstructured":"Tarumi T, Tomoto T, Repshas J, et al. Midlife aerobic exercise and brain structural integrity: associations with age and cardiorespiratory fitness. Neuroimage. 2021;225:117512.","journal-title":"Neuroimage"},{"key":"612_CR127","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/QAD.0000000000000580","volume":"29","author":"AM Dickens","year":"2015","unstructured":"Dickens AM, Anthony DC, Deutsch R, et al. Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients. AIDS. 2015;29:559\u201369.","journal-title":"AIDS"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-022-00612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-022-00612-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-022-00612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T10:24:26Z","timestamp":1676197466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-022-00612-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":127,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s11904-022-00612-2","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"2 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}